BEIJING, Nov. 4, 2015 /PRNewswire/ -- Today, Bloomage BioTechnology Corporation Limited ("Bloomage BioTech" or "the Company"; together with its subsidiaries, collectively referred to as "the Group", stock code: 00963) and GIC, Singapore's sovereign fund, jointly announced an investment agreement, pursuant to which GIC will become a key shareholder of the Company by subscribing for its shares to support the Company in building up the aesthetic medical ecosystem in China through organic growth and acquisitions. Pursuant to the agreement, GIC will make a total investment of HK$659 million into the Company, including subscription for HK$465 million convertible bonds and HK$194 million new shares, of which: This investment demonstrates the recognition of the Company's value by the world's leading sovereign fund, and great confidence in the Company's prospects and management team.